Artwork

Innhold levert av peopleofpathology. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av peopleofpathology eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Episode 183: Joseph Mossel - Revolutionizing Pathology with AI: A Conversation with IBEX Co-Founder

30:15
 
Del
 

Manage episode 422792301 series 3385006
Innhold levert av peopleofpathology. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av peopleofpathology eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Jospeh Mossel co-founded Ibex in 2016. Since its inception, Ibex has remained committed to developing AI applications for clinical diagnostics.

The company achieved its first milestone in 2018 by deploying its first algorithm for prostate cancer. This algorithm not only enhanced diagnostic efficiency but also detected a diagnostic error, demonstrating the value of AI in pathology.

Over the years, IBEX has expanded its offerings to include algorithms for breast and gastric cancers, facing challenges due to the unique characteristics of each tissue type. However, through partnerships with healthcare organizations and pharmaceutical companies, IBEX has continued to innovate and grow.

This conversation covers the history of Ibex and some of their milestones. We conclude with a look toward the future of AI in pathology.

Links for this episode:

Health Podcast Network

LabVine Learning

Dress A Med scrubs

Digital Pathology Club

Ibex Medical Analytics

An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study

People of Pathology Podcast:

Twitter

Instagram

  continue reading

190 episoder

Artwork
iconDel
 
Manage episode 422792301 series 3385006
Innhold levert av peopleofpathology. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av peopleofpathology eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Jospeh Mossel co-founded Ibex in 2016. Since its inception, Ibex has remained committed to developing AI applications for clinical diagnostics.

The company achieved its first milestone in 2018 by deploying its first algorithm for prostate cancer. This algorithm not only enhanced diagnostic efficiency but also detected a diagnostic error, demonstrating the value of AI in pathology.

Over the years, IBEX has expanded its offerings to include algorithms for breast and gastric cancers, facing challenges due to the unique characteristics of each tissue type. However, through partnerships with healthcare organizations and pharmaceutical companies, IBEX has continued to innovate and grow.

This conversation covers the history of Ibex and some of their milestones. We conclude with a look toward the future of AI in pathology.

Links for this episode:

Health Podcast Network

LabVine Learning

Dress A Med scrubs

Digital Pathology Club

Ibex Medical Analytics

An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study

People of Pathology Podcast:

Twitter

Instagram

  continue reading

190 episoder

所有剧集

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett